ORIC Pharmaceuticals Q3 2023 Earnings Report
Key Takeaways
ORIC Pharmaceuticals reported its Q3 2023 financial results, highlighting progress across its pipeline, including the presentation of initial Phase 1b data for ORIC-114, and steady enrollment across its three clinical trials. The company's cash and investments are expected to fund operations into late 2025.
Presented initial Phase 1b data for ORIC-114 in patients with EGFR and HER2 Exon 20 mutated NSCLC, demonstrating a potential best-in-class profile.
Initial Phase 1b data for ORIC-533 in patients with multiple myeloma to be presented at the 65th ASH Annual Meeting in December 2023.
Initial Phase 1b data for ORIC-944 in patients with prostate cancer expected in the first quarter of 2024.
Cash and investments of $256.2 million are expected to fund the operating plan into late 2025.
ORIC Pharmaceuticals
ORIC Pharmaceuticals
Forward Guidance
ORIC Pharmaceuticals expects to continue advancing its clinical programs and present initial data for ORIC-533 and ORIC-944 in the coming quarters. The company believes its current cash position is sufficient to fund operations into late 2025.
Positive Outlook
- Continued clinical development of ORIC-114.
- Advancement of ORIC-533 into clinical trials.
- Progress in the development of ORIC-944.
- Sufficient cash to fund operations into late 2025.
- Potential advantages of ORIC-114 and ORIC's other product candidates and programs.
Challenges Ahead
- Clinical outcomes of ORIC-114 may materially change as patient enrollment continues or more patient data become available.
- Changes in ORIC’s plans to develop and commercialize its product candidates.
- Potential for clinical trials of ORIC-114, ORIC-533, ORIC-944 or any other product candidates to differ from preclinical, initial, interim, preliminary or expected results.
- Negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials
- Reliance on third parties, including contract manufacturers and contract research organizations.